PulseSight Therapeutics is pioneering a unique approach to administer disease-modifying genes through its proprietary electro-transfection delivery device. Their innovative therapies offer longer-acting as well as more effective options than current treatments, addressing multiple pathways involved in the disease process.

Currently advancing two non-viral gene therapies PST-809 and PST-611 for wet and dry AMD using a proprietary, minimally-invasive administration technology, which allows an efficient long term delivery of therapeutic proteins in the retina.